1. >
  2. search-en


Found 417 Results
Page 1 of 42

Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities

Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally Cash position of €26.9 million as of June […]


High-Grade Glioma Relapse in Children: Onxeo announces the enrollment of the first patient in the phase 1b/2 clinical study conducted by the European ITCC consortium and sponsored by Institut Curie

Paris (France), September 1st, 2022 – 8 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North[1]: ONXEO), a […]


Onxeo announces that Nasdaq approved the delisting of its shares from the First North Growth market in Copenhagen

Last day of trading on the First North Growth market on November 8, 2022 Listing on Euronext Growth Paris remains […]


Combined General Meeting of August 17, 2022: Onxeo shareholders approve withdrawal from the Nasdaq First North market in Copenhagen

Company to submit delisting request to Nasdaq   Paris (France), August 17, 2022 – 08:00 pm CEST – Onxeo S.A. […]


Combined General Meeting of August 17, 2022: availability of preparatory documents and participation & voting procedures

Paris (France), July 29, 2022 – 06:30 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a […]


Onxeo announces a Combined General Meeting on August 17, 2022

Paris (France), July 12, 2022 – 07:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]


Initial IND application for AsiDNA Granted “Study May Proceed” by the U.S. FDA

Onxeo to initiate its first phase 1b/2 trial in the United States in patients with solid tumors   Paris (France), […]


Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022

All resolutions voted in accordance with Board of Directors’ recommendations Khalil Barrage, Managing Director of Invus’ public equity investments division, […]


Page 1 of 42

No more results